{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:39:06Z","timestamp":1773099546309,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,21]]},"DOI":"10.7759\/cureus.56637","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T14:51:41Z","timestamp":1711032701000},"source":"Crossref","is-referenced-by-count":2,"title":["Bilateral Cytomegalovirus Retinitis After Chimeric Antigen Receptor T-cell Therapy for B-cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Leo","family":"Meller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasan","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C","family":"Oca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Sestak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.305","article-title":"Complications, diagnosis, management, and prevention of CMV infections: current and future","volume":"2011","author":"Boeckh M","year":"2011","unstructured":"Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program. 2011, 2011:305-9. 10.1182\/asheducation-2011.1.305","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair M","year":"2019","unstructured":"Zuhair M, Smit GS, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019, 29:2034. 10.1002\/rmv.2034","journal-title":"Rev Med Virol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.75.888.585","article-title":"Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome","volume":"75","author":"Au Eong KG","year":"1999","unstructured":"Au Eong KG, Beatty S, Charles SJ. Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Postgrad Med J. 1999, 75:585-90. 10.1136\/pgmj.75.888.585","journal-title":"Postgrad Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0140","article-title":"Cytomegalovirus retinitis: a review","volume":"33","author":"Port AD","year":"2017","unstructured":"Port AD, Orlin A, Kiss S, Patel S, D'Amico DJ, Gupta MP. Cytomegalovirus retinitis: a review. J Ocul Pharmacol Ther. 2017, 33:224-34. 10.1089\/jop.2016.0140","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref5","article-title":"Cytomegalovirus retinitis in the era of highly active antiretroviral therapy","volume":"14","author":"Kedhar SR","year":"2007","unstructured":"Kedhar SR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes. 2007, 14:66-71.","journal-title":"Herpes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.62.6.2050-2058.1988","article-title":"Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture","volume":"62","author":"de la Torre JC","year":"1988","unstructured":"de la Torre JC, Mart\u00ednez-Salas E, Diez J, et al.. Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. J Virol. 1988, 62:2050-8. 10.1128\/JVI.62.6.2050-2058.1988","journal-title":"J Virol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June CH","year":"2018","unstructured":"June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018, 359:1361-5. 10.1126\/science.aar6711","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00418-1","article-title":"Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study","volume":"29","author":"Sheykhhasan M","year":"2022","unstructured":"Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 2022, 29:1080-96. 10.1038\/s41417-021-00418-1","journal-title":"Cancer Gene Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez JC","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019, 10:2040620719841581. 10.1177\/2040620719841581","journal-title":"Ther Adv Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird JH","year":"2021","unstructured":"Baird JH, Epstein DJ, Tamaresis JS, et al.. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021, 5:143-55. 10.1182\/bloodadvances.2020002732","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill JA","year":"2018","unstructured":"Hill JA, Li D, Hay KA, et al.. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018, 131:121-30. 10.1182\/blood-2017-07-793760","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/20499361211036773","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart AG","year":"2021","unstructured":"Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis. 2021, 8:20499361211036773. 10.1177\/20499361211036773","journal-title":"Ther Adv Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-320814","article-title":"Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review","volume":"107","author":"Mumtaz AA","year":"2023","unstructured":"Mumtaz AA, Fischer A, Lutfi F, et al.. Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. Br J Ophthalmol. 2023, 107:901-5. 10.1136\/bjophthalmol-2021-320814","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins S","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019, 94:3-9. 10.1002\/ajh.25418","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.2.84","article-title":"Investigation of CMV disease in immunocompromised patients","volume":"54","author":"Emery VC","year":"2001","unstructured":"Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol. 2001, 54:84-8. 10.1136\/jcp.54.2.84","journal-title":"J Clin Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.15386\/cjmed-587","article-title":"Cytomegalovirus infection in immunosuppressed patients after kidney transplantation","volume":"89","author":"Luscalov S","year":"2016","unstructured":"Luscalov S, Loga L, Dican L, Junie LM. Cytomegalovirus infection in immunosuppressed patients after kidney transplantation. Clujul Med. 2016, 89:343-6. 10.15386\/cjmed-587","journal-title":"Clujul Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030458","article-title":"Retinal vascular endothelial cell dysfunction and Neuroretinal degeneration in diabetic patients","volume":"10","author":"Mrugacz M","year":"2021","unstructured":"Mrugacz M, Bryl A, Zorena K. Retinal vascular endothelial cell dysfunction and Neuroretinal degeneration in diabetic patients. J Clin Med. 2021, 10:458. 10.3390\/jcm10030458","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.327","article-title":"Cytomegalovirus and the eye","volume":"26","author":"Carmichael A","year":"2012","unstructured":"Carmichael A. Cytomegalovirus and the eye. Eye (Lond). 2012, 26:237-40. 10.1038\/eye.2011.327","journal-title":"Eye (Lond)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8010055","article-title":"Cytomegalovirus retinitis in HIV and non-HIV individuals","volume":"8","author":"Munro M","year":"2019","unstructured":"Munro M, Yadavalli T, Fonteh C, Arfeen S, Lobo-Chan AM. Cytomegalovirus retinitis in HIV and non-HIV individuals. Microorganisms. 2019, 8:55. 10.3390\/microorganisms8010055","journal-title":"Microorganisms"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565060-00012","article-title":"Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients","volume":"65","author":"Cvetkovi\u0107 RS","year":"2005","unstructured":"Cvetkovi\u0107 RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005, 65:859-78. 10.2165\/00003495-200565060-00012","journal-title":"Drugs"},{"key":"ref21","article-title":"Efficacy and safety of a lower-dose valganciclovir (Valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients","volume":"35","author":"Bhat V","year":"2010","unstructured":"Bhat V, McIntyre M, Meyers T. Efficacy and safety of a lower-dose valganciclovir (Valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients. P T. 2010, 35:676-9.","journal-title":"P T"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2004.00066.x","article-title":"Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease","volume":"6","author":"Taber DJ","year":"2004","unstructured":"Taber DJ, Ashcraft E, Baillie GM, et al.. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004, 6:101-9. 10.1111\/j.1399-3062.2004.00066.x","journal-title":"Transpl Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25047","article-title":"Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients","volume":"24","author":"Khan S","year":"2018","unstructured":"Khan S, Sullivan T, Ali M, Dunn D, Patel G, Huprikar S. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients. Liver Transpl. 2018, 24:616-22. 10.1002\/lt.25047","journal-title":"Liver Transpl"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28111","article-title":"Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study","volume":"133","author":"Stragliotto G","year":"2013","unstructured":"Stragliotto G, Rahbar A, Solberg NW, et al.. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013, 133:1204-13. 10.1002\/ijc.28111","journal-title":"Int J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos I","year":"2021","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al.. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021, 49:215-31. 10.1007\/s15010-020-01521-5","journal-title":"Infection"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq143","article-title":"Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis","volume":"52","author":"Kalil AC","year":"2011","unstructured":"Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011, 52:313-21. 10.1093\/cid\/ciq143","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma N","year":"2022","unstructured":"Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy-a brief review of a complex problem. Cancers (Basel). 2022, 14:1501. 10.3390\/cancers14061501","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-12-963","article-title":"The diagnosis of cytomegalovirus retinitis","volume":"109","author":"Bloom JN","year":"1988","unstructured":"Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988, 109:963-9. 10.7326\/0003-4819-109-12-963","journal-title":"Ann Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23002","article-title":"Post-CD19 chimeric antigen receptor T-cell therapy cytomegalovirus retinitis","volume":"14","author":"Bin Dokhi H","year":"2022","unstructured":"Bin Dokhi H, Alharbi AO, Ibnouf NH, Alahmari B, Refka MN. Post-CD19 chimeric antigen receptor T-cell therapy cytomegalovirus retinitis. Cureus. 2022, 14:23002. 10.7759\/cureus.23002","journal-title":"Cureus"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29020044","article-title":"Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma","volume":"29","author":"Zu C","year":"2022","unstructured":"Zu C, Xu Y, Wang Y, et al.. Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma. Curr Oncol. 2022, 29:490-6. 10.3390\/curroncol29020044","journal-title":"Curr Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/218508-bilateral-cytomegalovirus-retinitis-after-chimeric-antigen-receptor-t-cell-therapy-for-b-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T14:51:45Z","timestamp":1711032705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/218508-bilateral-cytomegalovirus-retinitis-after-chimeric-antigen-receptor-t-cell-therapy-for-b-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.56637","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}